Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average recommendation of "Hold" from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $7.14.

A number of equities research analysts recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Bank of America reissued an "underperform" rating and set a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Finally, Mizuho increased their price objective on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Neumora Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company's stock worth $7,464,000 after acquiring an additional 5,899 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Neumora Therapeutics in the fourth quarter valued at approximately $64,000. Quantbot Technologies LP bought a new position in Neumora Therapeutics in the 4th quarter valued at approximately $92,000. PEAK6 LLC acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC bought a new stake in Neumora Therapeutics during the 4th quarter worth approximately $135,000. Institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Price Performance

NASDAQ NMRA traded up $0.44 on Monday, reaching $2.29. The stock had a trading volume of 2,985,505 shares, compared to its average volume of 2,273,010. The company has a market cap of $370.41 million, a P/E ratio of -1.42 and a beta of 2.75. The firm has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.22. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). Research analysts predict that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.